April 6th 2024
Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMML
April 3rd 2022AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.
Read More
Phase 1b/2 Study To Evaluate AUTO1 CAR T Cells in Relapsed/Refractory Adult B-Cell ALL
March 29th 2022Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Read More
FDA Postpones Decision on Luspatercept-aamt for Anemia in Adults With NTD Beta Thalassemia
March 25th 2022The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.
Read More
3 Trials Support Use of Naïve T-Cell Depletion Strategy in PBSC Grafts to Prevent Chronic GVHD
March 25th 2022Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.
Read More
Roundtable Discussion: Salit Explores Use of Steroids and Therapy for Acute GVHD
March 19th 2022During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.
Read More
Considerations When Selecting Patients With R/R Myeloma for Cilta-Cel Treatment
March 4th 2022Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.
Watch